Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Angiotensin II type 1 receptor antagonist decreases.

Slides:

Advertisements

Similar presentations

The Vicious Cycle of Chronic Congestive Heart Failure.

Advertisements

Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Randomized Trial to Assess Catheter Ablation Versus.

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Elevated Intra-Abdominal Pressure in Acute Decompensated.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cirrhotic Cardiomyopathy J Am Coll Cardiol. 2010;56(7):

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Renal Denervation in Moderate Treatment-Resistant.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Path to an Angiotensin Receptor Antagonist-Neprilysin.

Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Spectrum and prognostic significance of arrhythmias.

Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Understanding the Heterogeneity in Volume Overload.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effect of Serelaxin on Cardiac, Renal, and Hepatic.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effect of Serelaxin on Cardiac, Renal, and Hepatic.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Novel Contrast Removal System From the Coronary.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Survival of patients with diabetes and multivessel.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship Between Operator Volume and Adverse.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk Assessment and Comparative Effectiveness of.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Persistence of Iatrogenic Atrial Septal Defect After.

Date of download: 6/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Historical criteria that distinguish syncope from.

Date of download: 6/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Quality of Care of and Outcomes for African Americans.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Rapid improvement of nitric oxide bioavailability.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Improved Survival of Patients With End-Stage Heart.

Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Does acute improvement of endothelial dysfunction.

Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Aspirin Administered at Bedtime, But Not on Awakening,

Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Loss of Cardiac Magnesium in Experimental Heart.

Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prognostic implications of atrial fibrillation in.

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Irbesartan, an angiotensin type 1 receptor inhibitor,

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Overview of the 2011 Food and Drug Administration.

Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Myocardial Microvascular Inflammatory Endothelial.

Date of download: 6/25/2016 Copyright © 2016 American Medical Association. All rights reserved. From: BNP-Guided vs Symptom-Guided Heart Failure Therapy:

Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Influence of Left Ventricular Ejection Fraction.

Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardio-Pulmonary-Renal Interactions: A Multidisciplinary.

Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Acute changes in circulating natriuretic peptide.

Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Utility of B-type natriuretic peptide in the diagnosis.

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.

Date of download: 7/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Treatment of Chronic Functional Mitral Valve Regurgitation.

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardiopoietic Stem Cell Therapy in Heart Failure:

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Ventricular Arrhythmia After Cardiac Surgery: Incidence,

Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Obstructive Sleep Apnea and Heart Failure: Pathophysiologic.

Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: Acute Phosphodiesterase 5 Inhibition Mimics Hemodynamic.

Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for the management of patients.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Angiotensin-converting enzyme inhibition reduces.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Association of cardiac troponin, CK-MB, and postoperative.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Modified Serum Profiles of Inflammatory and Vasoconstrictive.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Tolerability and efficacy of carvedilol in patients.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Natriuretic Peptides Enhance the Production of Adiponectin.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of Low-Dose Human Atrial Natriuretic Peptide.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pulmonary Arterial Hypertension J Am Coll Cardiol.

Date of download: 7/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Role of the Natriuretic Peptide System in Cardiorenal.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Local Renal Delivery of a Natriuretic Peptide: A.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pro–Atrial Natriuretic Peptide: A Novel Guanylyl.

Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Spironolactone inhibits the transcardiac extraction.

Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pulmonary Valve Replacement After Operative Repair.

Date of download: 7/11/2016 Copyright © The American College of Cardiology. All rights reserved. From: Does subclinical hypothyroidism affect cardiac pump.

Date of download: 7/16/2016 Copyright © The American College of Cardiology. All rights reserved. From: Metabolic Impairment in Heart Failure: The Myocardial.

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship between tumor necrosis factor-alpha.

Date of download: 11/11/2016 Copyright © The American College of Cardiology. All rights reserved. From: Targeted Left Ventricular Lead Placement to Guide.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: N-terminal pro brain natriuretic peptide on admission.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: LV Noncompaction Cardiomyopathy or Just a Lot of.

Date of download: 11/13/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Reality of Heart Failure in Latin America J.

Atrial Natriuretic Peptides [ANP]

J Am Coll Cardiol Img. 2012;5(11): doi: /j.jcmg Figure Legend:

Copyright © 2006 American Medical Association. All rights reserved.

Chronic Vagus Nerve Stimulation Improves Autonomic Control and Attenuates Systemic Inflammation and Heart Failure Progression in a Canine High-Rate Pacing.

Changes in plasma Ald, Ang II and ANP concentrations before and after 4-day head-down bed rest (HDBR) in both the control (Con) and transcutaneous electrical.

Eugene Braunwald JCHF 2013;1:1-20

Atrial Natriuretic Peptides [ANP]

Antoni Bayés-Genís JCHF 2015;3:

Sexual Activity and Chronic Heart Failure

Volume 67, Issue 5, Pages (May 2005)

Postoperative synthetic human atrial natriuretic peptide infusion and oral spironolactone administration for a patient with giant atria and low plasma.

Fig. 11. Role of endothelial dysfunction in the progression of chronic cardiac failure. The diagram depicts the four major underlying and mutually interacting.

Presentation transcript:

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure J Am Coll Cardiol. 2000;35(3): doi: /S (99)00594-X Figure Legend: Hemodynamic parameters and functional class before and after 14 weeks of treatment with candesartan cilexetil in 14 patients with mild to moderate congestive heart failure. HR = heart rate; LVEDV = left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic volume; MBP = mean blood pressure; NYHA = New York Heart Association. ∗ p < 0.05; ∗∗ p < 0.01 vs. before.

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure J Am Coll Cardiol. 2000;35(3): doi: /S (99)00594-X Figure Legend: Plasma levels of active renin concentration (PARC), angiotensin (Ang II), aldosterone (ALD) and norepinephrine (NE) before and after 14 weeks of treatment with candesartan cilexetil in 14 patients with mild to moderate congestive heart failure. ∗ p < 0.05; ∗∗ p < 0.01 vs. before.

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure J Am Coll Cardiol. 2000;35(3): doi: /S (99)00594-X Figure Legend: Plasma levels of endothelin-1 (ET-1), atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and cyclic guanosine monophosphate (cGMP) before and after 14 weeks of treatment with candesartan cilexetil in 14 patients with mild to moderate congestive heart failure. ∗ p < 0.05 vs. before.

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure J Am Coll Cardiol. 2000;35(3): doi: /S (99)00594-X Figure Legend: Plasma levels of interleukin-6 (IL-6), tumor necrosis factor alpha (TNFα), soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular adhesion molecule-1 (sVCAM-1) before and after 14 weeks of treatment with candesartan cilexetil in 14 patients with mild to moderate congestive heart failure. ∗ p < 0.05 vs. before.

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure J Am Coll Cardiol. 2000;35(3): doi: /S (99)00594-X Figure Legend: The molar ratio of plasma cGMP (cyclic guanosine monophosphate) to cardiac natriuretic peptides before and after 14 weeks of treatment with candesartan cilexetil (closed columns) or placebo (open columns). ANOVA = analysis of variance; ANP = atrial natriuretic peptide; BNP = brain natriuretic peptide. ∗ p < 0.05 vs. before with a two-way ANOVA by Scheffé F test.